

<b>Division of Compensation Analysis and Support</b> <b>Program Evaluation Report</b>	Document Number: DCAS-PER-069 Effective Date: 4/5/2016 Revision No. 0
<b>Jessop Steel Company</b>	
Page 1 of 2	
Author: <u>Signature on file</u> Dave Allen, HP Team Leader	Date: <u>4/5/2016</u>
Supersedes: None	
Approval: <u>Signature on file</u> J.W. Neton, Associate Director for Science	Date: <u>4/5/2016</u>

RECORD OF ISSUE/REVISIONS			
ISSUE AUTHORIZATION DATE	EFFECTIVE DATE	REV. NO.	DESCRIPTION
4/5/2016	4/5/2016	0	New document to determine the effect of the revision to Appendix BL of Battelle-TBD-6000 (Jessop) on previously completed claims.

### 1.0 Description

Dose reconstructions for the claims from the Jessop Steel Company (Jessop) are performed using Appendix BL of Battelle-TBD-6000. The Appendix was originally issued on 5/25/2007. Revision 1 to that document was issued on 10/19/2015. This PER (DCAS-PER-069) evaluates the effect of revision 1 on all previously completed claims.

### 2.0 Issue Evaluation

Revision 1 of Appendix BL was an update to incorporate changes made to Battelle-TBD-6000. Additional changes were made to make the dose estimate more consistent with existing techniques. One of the results of these changes is an increase in inhalation intakes. That change increases the dose estimate for all claims completed using an earlier version. Therefore, it was not necessary to itemize any other increases in dose or further breakdown the time periods affected.

### 3.0 Plan for Resolution or Corrective Action

In order to evaluate the effect of revision 1 of the Appendix on all previously completed claims, a search was conducted for all completed claims with verified employment at the Jessop site during the covered period and that had a probability of causation (POC) of less than 50%. This search identified 8 claims.

<b>Division of Compensation Analysis and Support Program Evaluation Plan</b>	Document Number: DCAS-PER-069
Effective Date: 4/5/2016      Revision No. 0	Page 2 of 2

A new dose estimate was performed for each of the 8 claims using revision 1 of the Appendix, as well as all other applicable approved dose reconstruction methods. The resulting probability of causation (POC) was below 45% for all 8 claims.

NIOSH will provide the Department of Labor with the list of all claims evaluated under this PER. Since none would now result in a POC greater than 50%, NOSH will not request the return of any of the claims.